Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday - Angel Studios ( NYSE:ANGX )
U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday. Shares of Taysha Gene Therapies Inc ( NASDAQ:TSHA ) rose sharply during Thursday's session after the FDA granted the company Breakthrough Therapy designation to TSHA-102 for the treatment of Rett syndrome.
This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - FactSet Research Systems ( NYSE:FDS ) , Brinker International ( NYSE:EAT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Barclays analyst Eddie Kim upgraded Helmerich & Payne, Inc.
2 Beaten-Down Stocks to Avoid Right Now
These once high-flying stocks no longer seem to have promising prospects.
Top 20 Most-Searched Stock Tickers on Pro in August - Apple ( NASDAQ:AAPL )
A look at the 20 most-searched tickers on Benzinga Pro for the month of August. The list includes two companies buying up Ethereum for their balance sheets. Get a Year of Fast, Actionable Trade Alerts for 60% Off This Labor Day
SRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class Action - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN DIEGO, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. SRPT securities between June 22, 2023 and June 24, 2025.
Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ( "Sarepta" or the "Company" ) SRPT of a class action securities lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ( "Sarepta" or the "Company" ) SRPT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ( or ...
Muscular Dystrophy Association Launches #MDAstrong Campaign in September During Historic 75th Anniversary, Kicking Off on Labor Day Weekend
New York, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- This September, the Muscular Dystrophy Association ( MDA ) is launching its milestone #MDAstrong campaign during a historic moment for the organization: its 75th anniversary.
SRPT FINAL DEADLINE ALERT: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline in Securities Class Action - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN FRANCISCO, Aug. 23, 2025 ( GLOBE NEWSWIRE ) -- A securities class-action lawsuit is underway against Sarepta Therapeutics SRPT, triggered by a series of safety concerns and regulatory setbacks for its gene therapy, ELEVIDYS. The lawsuit alleges that Sarepta misled investors by presenting ...
MONDAY INVESTOR DEADLINE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT
MONDAY INVESTOR DEADLINE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit ...
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options
SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 23, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
SRPT 3-DAY DEADLINE ALERT: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN FRANCISCO, Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- A securities class-action lawsuit is underway against Sarepta Therapeutics SRPT, triggered by a series of safety concerns and regulatory setbacks for its gene therapy, ELEVIDYS. The lawsuit alleges that Sarepta misled investors by presenting ...
SRPT FINAL DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 25 Deadline in Securities Class Action - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. SRPT between June 22, 2023 and June 24, 2025, both dates inclusive ( the "Class Period" ) , of the important August 25, 2025 ...
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ( "Sarepta" or the "Company" ) SRPT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ( or ...
What's Going On With Sarepta Shares Thursday? - Sarepta Therapeutics ( NASDAQ:SRPT )
Sarepta swaps $700 million of 2027 notes for $602 million of new 2030 notes, stock, and cash. The new notes convert at $60 per share, a 191.5% premium to the last close of $20.58. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here →
SRPT DEADLINE NOTICE: Sarepta Therapeutics, Inc. Investors are Notified of the August 25 Class Action Deadline -- Contact BFA Law if You Suffered Losses ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
INVESTOR DEADLINE MONDAY: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN DIEGO, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. SRPT securities between June 22, 2023 and June 24, 2025, inclusive ( the "Class Period" ) , have until Monday, August 25, 2025 to seek appointment ...
SRPT Update: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN FRANCISCO, Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- A securities class-action lawsuit is underway against Sarepta Therapeutics SRPT, triggered by a series of safety concerns and regulatory setbacks for its gene therapy, ELEVIDYS. The lawsuit alleges that Sarepta misled investors by presenting ...
SRPT Investors Have the Opportunity to Lead the Sarepta Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Sarepta Therapeutics ( NASDAQ:SRPT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options
SRPT SECURITIES: Sarepta Therapeutics, Inc. Shareholders that Lost Money may have been Affected by Fraud -- Contact BFA Law before the Class Action Deadline ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
Robbins LLP Reminds Sarepta Therapeutics, Inc. Stockholders of the Pending Lead Plaintiff Deadline in the Securities Class Action Against SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN DIEGO, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. SRPT securities between June 22, 2023 and June 24, 2025.
Contact The Gross Law Firm by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc. ( SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. SRPT. Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff ...
Sarepta Therapeutics ( SRPT ) August 25, 2025 Lead Plaintiff Deadline Approaching, SRPT Investors with Substantial Losses Encouraged to Contact Hagens Berman - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN FRANCISCO, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- The pending securities class action was triggered after news of safety problems with Sarepta's SRPT ELEVIDYS, a medication intended for the treatment of Duchenne muscular dystrophy.
SRPT INVESTOR NOTICE: Robbins Geller Ruman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN DIEGO, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc.
SRPT LOSS ALERT: Sarepta Therapeutics, Inc. Investors with Losses are Reminded of the August 25 Class Action Deadline - Contact BFA Law ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 17, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
SRPT IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 25 Deadline in Securities Class Action - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 16, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. SRPT between June 22, 2023 and June 24, 2025, both dates inclusive ( the "Class Period" ) , of the important August 25, 2025 ...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - Sarepta Therapeutics ( NASDAQ:SRPT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options
SAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th Deadline - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 16, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ( "Sarepta" or the "Company" ) SRPT in the United States District Court for the ...
SRPT FRAUD REMINDER: Sarepta Therapeutics, Inc. Stock Drop Triggers Securities Fraud Class Action - Contact BFA Law before Imminent August 25 Deadline ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 15, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
Sarepta Sells Arrowhead Stake to Fund Milestone Payment
Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.
How Do Investors Really Feel About Sarepta Therapeutics? - Sarepta Therapeutics ( NASDAQ:SRPT )
Sarepta Therapeutics's SRPT short percent of float has risen 41.95% since its last report. The company recently reported that it has 20.95 million shares sold short, which is 25.14% of all regular shares that are available for trading.
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - Sarepta Therapeutics ( NASDAQ:SRPT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options
SAREPTA ( SRPT ) LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ( "Sarepta" or the "Company" ) SRPT in the United States District Court for the ...
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction - Cabaletta Bio ( NASDAQ:CABA ) , Moderna ( NASDAQ:MRNA )
Vinay Prasad returns as FDA's CBER head days after resigning amid Sarepta drug controversy. Analysts see a possible softer stance on rare disease therapies under Prasad. Get ahead of next week's CPI & PPI with Chris Capre's live trading strategy session this Sunday. Register Now →
C3.ai, Destiny Tech100 And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Ambiq Micro ( NYSE:AMBQ ) , C3.ai ( NYSE:AI )
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday. Shares of C3.ai, Inc. AI fell sharply in pre-market trading after the company reported preliminary first-quarter revenue of $70.2 million to $70.4 million with GAAP operating loss of up to $124.9 million.
SRPT COURT NOTICE: Sarepta Therapeutics Investors may have been Affected by Fraud -- Contact BFA Law before August 25 if You Suffered Losses ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket - ALT5 Sigma ( NASDAQ:ALTS ) , C3.ai ( NYSE:AI )
Shares of International Money Express, Inc. IMXI rose sharply in pre-market trading after Western Union announced plans to acquire Intermex for $500 million. Western Union revealed its plans to acquire Intermex, a U.S.-based company specializing in payment transfers to Latin America and the ...
SRPT DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. SRPT between June 22, 2023 and June 24, 2025, both dates inclusive ( the "Class Period" ) , of the important August 25, 2025 ...
Arrowhead ( ARWR ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, August 7, 2025 at 8:30 p.m. ETPresident and Chief Executive Officer - Dr. Christopher AnzaloneContinue reading ...
Arrowhead ( ARWR ) Q3 Revenue Drops 41%
Arrowhead Pharmaceuticals ( NASDAQ:ARWR ) , a biotechnology firm focused on developing RNA interference ( RNAi ) therapeutics, released its fiscal third-quarter earnings on August 7, 2025. The most notable news from the release was a substantial miss on both GAAP revenue and earnings for Q3 ...
Sarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion.
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Sarepta Therapeutics, Inc. ( "Sarepta Therapeutics" or the "Company" ) ( NASDAQ.
Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries
SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.
SRPT SHAREHOLDERS: Sarepta Therapeutics Stock Drop Triggers Securities Fraud Class Action - Contact BFA Law by August 25 if You Lost Money ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
Sarepta Therapeutics ( SRPT ) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing Authorization, Securities Class Action Pending - Hagens Berman - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN FRANCISCO, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- On July 24, 2025, the European Medicines Agency ( "EMA" ) recommended the refusal of the marketing authorization for ELEVIDYS, Sarepta's medication intended for the treatment of Duchenne muscular dystrophy.
Sarepta Therapeutics ( SRPT ) Tops Q2 Earnings and Revenue Estimates
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +81.98% and +15.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
SAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ( "Sarepta" or the "Company" ) SRPT in the United States District Court for the ...
SRPT CLASS ACTION: Sarepta Therapeutics Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by August 25 Legal Deadline ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer - Vor Biopharma ( NASDAQ:VOR )
CAMBRIDGE, Mass., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Vor Bio VOR, a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Dallan Murray as Chief Commercial Officer, effective immediately.
